COLD + SINUS CAPLETS TABLET

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

Disponibbli minn:

VITA HEALTH PRODUCTS INC

Kodiċi ATC:

M01AE51

INN (Isem Internazzjonali):

IBUPROFEN, COMBINATIONS

Dożaġġ:

200MG; 30MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

IBUPROFEN 200MG; PSEUDOEPHEDRINE HYDROCHLORIDE 30MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

10/20

Tip ta 'preskrizzjoni:

OTC

Żona terapewtika:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0222394001; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2006-10-17

Karatteristiċi tal-prodott

_ _
_Page 1 of 50_
PRODUCT MONOGRAPH
COLD + SINUS CAPLETS
Ibuprofen and Pseudoephedrine Hydrochloride Tablets USP
Ibuprofen 200 mg, Pseudoephedrine Hydrochloride 30 mg
USP
Analgesic/Antipyretic/Nasal Decongestant
Vita Health Products Inc.
150 Beghin Avenue
Winnipeg, Manitoba
Canada, R2J 3W2
Control No. 151199
Date of Revision:
January 30, 2012
_ _
_ _
_Page 2 of 50_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
ADVERSE
REACTIONS..................................................................................................11
DRUG INTERACTIONS
..................................................................................................17
DOSAGE AND
ADMINISTRATION..............................................................................20
OVERDOSAGE
...............................................................................................................21
ACTION AND CLINICAL PHARMACOLOGY
............................................................23
STORAGE AND
STABILITY..........................................................................................28
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................28
PART II: SCIENTIFIC INFORMATION
...............................................................................29
PHARMACEUTICAL
INFORMATION..........................................................................29
CLINICAL
TRIALS..........................................................................................................31
DETAILED
PHARMACOLOGY.....................................................................................33
TOXICOLOGY
.......